Royal Bank of Canada’s AbbVie ABBV Stock Holding History

Royal Bank of Canada’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.57M	Buy	+30,200	New	+$6.7M	﹤0.01%	2215
2025 Q2	–	Sell	-14,000	Closed	-$2.93M	–	6977
2025 Q1	$2.93M	Sell	14,000 -6,000	-30%	-$1.17M	﹤0.01%	2659
2024 Q4	$3.55M	Hold	20,000	–	–	﹤0.01%	2594
2024 Q3	$3.95M	Hold	20,000	–	–	﹤0.01%	2462
2024 Q2	$3.43M	Hold	20,000	–	–	﹤0.01%	2486
2024 Q1	$3.64M	Sell	20,000 -300	-1%	-$51.7K	﹤0.01%	2434
2023 Q4	$3.15M	Hold	20,300	–	–	﹤0.01%	2659
2023 Q3	$3.03M	Hold	20,300	–	–	﹤0.01%	2493
2023 Q2	$2.73M	Buy	20,300 +20,000	+6,667%	+$2.93M	﹤0.01%	2593
2023 Q1	$48K	Sell	300 -37,000	-99%	-$5.66M	﹤0.01%	5643
2022 Q4	$6.03M	Buy	37,300 +20,000	+116%	+$3.07M	﹤0.01%	1998
2022 Q3	$2.32M	Buy	17,300 +300	+2%	+$43K	﹤0.01%	2719
2022 Q2	$2.6M	Hold	17,000	–	–	﹤0.01%	2640
2022 Q1	$2.76M	Sell	17,000 -164,600	-91%	-$23.9M	﹤0.01%	2762
2021 Q4	$24.6M	Hold	181,600	–	–	0.01%	1261
2021 Q3	$19.6M	Sell	181,600 -118,800	-40%	-$13.6M	0.01%	1360
2021 Q2	$33.8M	Buy	300,400 +400	+0.1%	+$45K	0.01%	977
2021 Q1	$32.5M	Buy	300,000 +53,700	+22%	+$5.74M	0.01%	956
2020 Q4	$26.4M	Hold	246,300	–	–	0.01%	1073
2020 Q3	$21.6M	Sell	246,300 -39,000	-14%	-$3.67M	0.01%	1029
2020 Q2	$28M	Sell	285,300 -75,000	-21%	-$6.6M	0.01%	847
2020 Q1	$27.5M	Buy	360,300 +119,400	+50%	+$10.2M	0.01%	739
2019 Q4	$21.3M	Buy	240,900 +68,500	+40%	+$5.69M	0.01%	1127
2019 Q3	$13.1M	Buy	172,400 +106,100	+160%	+$7.27M	0.01%	1357
2019 Q2	$4.82M	Buy	66,300 +300	+0.5%	+$23.6K	﹤0.01%	2101
2019 Q1	$5.32M	Sell	66,000 -149,300	-69%	-$12.2M	﹤0.01%	1963
2018 Q4	$19.8M	Buy	215,300 +35,300	+20%	+$3.1M	0.01%	996
2018 Q3	$17M	Hold	180,000	–	–	0.01%	1244
2018 Q2	$16.7M	Sell	180,000 -60,000	-25%	-$5.86M	0.01%	1191
2018 Q1	$22.7M	Buy	240,000 +131,300	+121%	+$14.4M	0.01%	1010
2017 Q4	$10.5M	Hold	108,700	–	–	﹤0.01%	1576
2017 Q3	$9.66M	Sell	108,700 -149,700	-58%	-$11.4M	﹤0.01%	1560
2017 Q2	$18.7M	Sell	258,400 -1,000	-0.4%	-$67.2K	0.01%	1096
2017 Q1	$16.9M	Buy	259,400 +82,900	+47%	+$5.21M	0.01%	1134
2016 Q4	$11.1M	Buy	176,500 +4,800	+3%	+$293K	0.01%	1440
2016 Q3	$10.8M	Sell	171,700 -55,400	-24%	-$3.59M	0.01%	1424
2016 Q2	$14.1M	Sell	227,100 -299,700	-57%	-$18.3M	0.01%	1207
2016 Q1	$30.1M	Buy	526,800 +443,700	+534%	+$24.7M	0.02%	683
2015 Q4	$4.92M	Buy	83,100 +1,000	+1%	+$57.6K	﹤0.01%	1881
2015 Q3	$4.47M	Buy	+82,100	New	+$5.34M	﹤0.01%	1647
2015 Q2	–	Sell	-960,000	Closed	-$56.2M	–	6557
2015 Q1	$56.2M	Buy	960,000 +779,500	+432%	+$47.1M	0.04%	352
2014 Q4	$11.8M	Buy	180,500 +500	+0.3%	+$31.5K	0.01%	1123
2014 Q3	$10.4M	Buy	+180,000	New	+$9.99M	0.01%	1191

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada's ABBV Position: Q1 2026 in Review

Royal Bank of Canada reduced its AbbVie (ABBV) stake by 4.5% in Q1 2026, selling an estimated $78.9M and leaving 7,534,148 shares worth $1.64B. The position accounts for 0.29% of the portfolio, ranked #64.

Royal Bank of Canada first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.94B in Q3 2025. 4,088 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Royal Bank of Canada held 7,534,148 shares of AbbVie worth $1.64B as of Q1 2026.
Royal Bank of Canada sold 355,721 AbbVie shares in Q1 2026, an estimated $78.9M.
AbbVie made up 0.29% of Royal Bank of Canada's portfolio in Q1 2026, its #64 holding.
Royal Bank of Canada first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's AbbVie position peaked at $1.94B in Q3 2025.
4,088 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.